Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2- metastatic breast cancer

Fig. 1

Identification of tumor and non-tumor cells. A Schematic depicting the study design, including 8 BL samples, 3 EP samples, and 7 LP samples from patients with HR+/HER2- mBC on CDK4/6i treatment. The cutoff for EP versus LP samples was a PFS duration of 6 months. B Study workflow illustrating sample processing, tumor cell identification (inferred by the presence of copy number aberrations using InferCNV), and downstream analysis. C UMAP plot of 18 samples in the embedding space. D Bar plot showing the relative fraction of tumor versus non-tumor cells for each sample, stratified by different sample statuses (BL, EP, and LP). E UMAP plot of tumor cells (left, pink) versus non-tumor cells (right, blue) without (top) or with (bottom) Harmony integration. F UMAP plot of cells, stratified by different sample statuses (BL, EP, and LP). G Heatmap displaying the expression of the top 15 differentially expressed genes, stratified by different sample statuses (BL, EP, and LP). H Predictive biomarker panels generated from the top differentially expressed genes from BL tumor cells. I Hallmark pathway analysis in tumor cells. The dot size represents the percentage of cells with the expression of certain genes under each sample status

Back to article page

Molecular Cancer

ISSN: 1476-4598